- Home
- SCNX vs RKTO Comparison
SCNX vs RKTO Comparison
Compare SCNX & RKTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SCNX | RKTO |
|---|---|---|
| Founded | 2010 | N/A |
| Country | United States | United States |
| Employees | 19 | 3 |
| Industry | Other Pharmaceuticals | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.0M | 20.3M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | SCNX | RKTO |
|---|---|---|
| Price | $0.42 | $0.84 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $1.50 | N/A |
| AVG Volume (30 Days) | 891.1K | ★ 7.0M |
| Earning Date | 05-13-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1,097.38 | N/A |
| Revenue Next Year | $239.80 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.24 | $0.76 |
| 52 Week High | $2.60 | $1.19 |
Technical Indicators
Market Signals| Indicator | SCNX | RKTO |
|---|---|---|
| Relative Strength Index (RSI) | 65.42 | 40.04 |
| Support Level | $0.38 | $0.80 |
| Resistance Level | $0.43 | $1.19 |
| Average True Range (ATR) | 0.04 | 0.10 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 91.70 | 17.63 |
Price Performance
Historical ComparisonAbout SCNX Scienture Holdings Inc.
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on providing value to patients and caregivers by offering novel specialty products to satisfy unmet market needs and optimize the prescription journey and patient engagement in the U.S.
About RKTO Rocket One Inc. Common Stock
Rocket One Inc is focused on developing and commercializing infrastructure for the orbital economy, including next-generation nanomagnetic AI chip technology designed for radiation-tolerant, energy-constrained environments such as low-Earth orbit, deep-space platforms, and defense systems. The company also intends to pursue opportunities related to nano-launch systems and nanosatellite deployment. In addition, its biotechnology operations, conducted through a wholly owned subsidiary, include development programs such as HT-001, HT-KIT, HT-ALZ, and a GDNF-based metabolic program.